{"gene":"FOSL1","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1988,"finding":"FRA-1 (fra-1) was identified as a serum-inducible immediate-early gene encoding a protein with extensive amino acid homology to c-Fos, including the region showing similarity to the yeast GCN4 regulatory protein and the Jun oncogene product. Unlike c-fos, fra-1 induction by serum was delayed, but it was induced rapidly in the presence of protein synthesis inhibitors, establishing it as an immediate-early gene.","method":"cDNA library screening with anti-Fos antibodies, nucleotide sequencing, Northern blot analysis of serum-stimulated rat fibroblasts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — original molecular characterization with cloning, sequencing, and direct functional comparison; foundational paper replicated by entire field","pmids":["3133553"],"is_preprint":false},{"year":1995,"finding":"Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron, which contain a consensus AP-1 site and two AP-1-like elements. Fra-1 protein fused to the Gal4 DNA-binding domain lacks transactivation function, yet overexpression of Fra-1 in rat fibroblasts confers anchorage-independent growth in vitro and tumor development in athymic mice, demonstrating oncogenic potential independent of classical transactivation.","method":"In vitro mutagenesis, stable transfection reporter assays, FosER induction system, soft-agar colony formation, nude mouse tumor assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, reporter assay, in vivo tumorigenesis), replicated concept","pmids":["7791782"],"is_preprint":false},{"year":1998,"finding":"Exogenous expression of Fra-1 in epithelioid CSML0 carcinoma cells induces morphological fibroblastoid conversion, increases motility and in vitro invasiveness, and transcriptionally activates genes associated with late-stage tumor progression, establishing a direct causal role for Fra-1 in epithelial-to-mesenchymal-like transition.","method":"Retroviral transduction of Fra-1 into CSML0 cells, invasion assay, morphological analysis, AP-1 EMSA, gene expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function with defined phenotypic readout, replicated by multiple subsequent studies","pmids":["9819396"],"is_preprint":false},{"year":1999,"finding":"Fra-1 (but not c-Fos) expressed by retroviral transduction in osteoclast-macrophage precursor cell lines causes a 10–100-fold increase in the number of precursors developing calcitonin receptors and increased bone resorption, suggesting Fra-1 is a limiting factor for full osteoclast differentiation distinct from c-Fos.","method":"Retroviral gene transfer into osteoclast precursor cell lines, calcitonin receptor assay, bone resorption assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct gain-of-function in relevant cell type, single lab, two readouts","pmids":["10199556"],"is_preprint":false},{"year":2000,"finding":"Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation: RANKL induces Fosl1 transcription in a c-Fos-dependent manner. All four Fos proteins (including Fra-1, which lacks transactivation domains) rescue the osteoclast differentiation block in c-fos-null mice when introduced by retroviral gene transfer; a Fra-1 transgene rescues osteopetrosis in c-fos-mutant mice in vivo.","method":"Retroviral gene transfer, transgenic mouse rescue, in vitro osteoclast differentiation assay, structure-function analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro and in vivo genetic rescue experiments with structure-function analysis, high-impact replicated findings","pmids":["10655067"],"is_preprint":false},{"year":2002,"finding":"Fra-1 activates AP-1-dependent transcription in an ERK-dependent manner: a putative ERK phosphorylation site on Fra-1 must be intact for its transactivation activity. Fra-1 was identified as the distinguishing AP-1 component in mitogen-activated (transformation-sensitive) JB6 cells. Introduction of a Fra-1 expression construct into an AP-1-nonresponsive variant that underexpresses Fra-1 restored AP-1 response.","method":"Site-directed mutagenesis of Fra-1 transactivation domain, gel shift/EMSA analysis, AP-1 reporter assays, ERK-deficient cell lines","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of ERK phosphorylation site combined with rescue experiment in isogenic cell lines","pmids":["11756554"],"is_preprint":false},{"year":2002,"finding":"Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal light-induced apoptosis. In knock-in mice expressing Fra-1 in place of c-Fos (Fos(Fosl1/Fosl1)), morphological features of apoptosis and AP-1 activity were indistinguishable from wild-type, demonstrating that Fra-1 can mediate both pro- and anti-apoptotic signaling without classic transactivation domains.","method":"Knock-in mouse model, light-damage apoptosis assay, AP-1 EMSA/supershift, histology","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic knock-in model with multiple orthogonal readouts","pmids":["11953459"],"is_preprint":false},{"year":2003,"finding":"MEK5-ERK5 pathway activation causes phosphorylation and stabilization of Fra-1, and the C-terminal half of ERK5 is required for maximal activation of Fra-1 transactivation activity. The MEK5-ERK5 pathway-dependent phosphorylation sites on Fra-1 are distinct from those of the ERK1/2 pathway.","method":"Constitutively active MEK5 expression, kinase inhibitor experiments, transactivation reporter assays, phosphorylation analysis","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporters and phosphorylation analyses, single lab","pmids":["12622723"],"is_preprint":false},{"year":2003,"finding":"Ras oncogene-dependent accumulation of Fra-1 requires both transcriptional autoregulation (via an AP-1 site in the fra-1 first intron occupied by Fra-1-containing complexes) and MEK/ERK-dependent posttranslational stabilization that dramatically increases Fra-1 protein half-life. Fra-1 transactivating activity in ras-transformed cells requires heterodimerization with a partner protein.","method":"Retroviral transformation of thyroid cells, chromatin immunoprecipitation, MEK inhibitor treatment, protein half-life analysis, transcriptional reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (ChIP, protein stability, reporter assay, MEK inhibition) in single rigorous study","pmids":["12773579"],"is_preprint":false},{"year":2003,"finding":"Fra-1 targets the AP-1 site adjacent to the 2G SNP in the MMP-1 promoter and is necessary for MMP-1 transcription in A2058 melanoma cells. Inhibition of Fra-1 expression preferentially downregulates transcription from the 2G SNP-containing MMP-1 promoter compared to the 1G SNP version.","method":"Fra-1 siRNA/antisense inhibition, MMP-1 promoter reporter assays with 1G vs 2G SNP constructs","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with promoter variant readout, single lab","pmids":["14519134"],"is_preprint":false},{"year":2007,"finding":"Fra-1 and Stat3 synergistically activate the MMP-9 gene promoter. DNA affinity precipitation and co-immunoprecipitation identified Stat3/Fra-1 and Stat3/c-Jun complexes in vivo, with c-Jun recruited to the Stat3-Fra-1 complex. A juxtaposed Stat3/AP-1 element in the MMP-9 promoter functions as an enhancersome. Neither Fra-1 alone nor Stat3 alone was sufficient for MMP-9 promoter activation.","method":"Luciferase reporter assays, DNA affinity precipitation assay, co-immunoprecipitation, promoter mutagenesis","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and functional reporter assay, single lab","pmids":["17572495"],"is_preprint":false},{"year":2007,"finding":"Ubiquitin-independent proteasomal degradation is a major pathway for Fra-1 turnover. Fra-1 shares a conserved destabilizing domain with c-Fos. Under particular conditions a fraction of cytoplasmic c-Fos is ubiquitylated leading to faster turnover, indicating multiple degradation pathways can target Fra-1 depending on activation state, protein partnership, and subcellular localization.","method":"Protein stability assays, proteasome inhibitor treatment, mutagenesis of destabilizing domains, subcellular fractionation","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic review with original data synthesis; degradation pathway established by multiple earlier experiments summarized","pmids":["17825471"],"is_preprint":false},{"year":2009,"finding":"Fra-1 binds to the MGP promoter in response to inorganic phosphate in osteoblasts, as demonstrated by in vitro DNA binding and chromatin immunoprecipitation assays. Pi-dependent induction of MGP is mediated through the ERK1/2-Fra-1 pathway: MEK1/2 inhibition abolishes Pi-stimulated Fra-1 and MGP expression, and primary osteoblasts from Fra-1-deficient mice fail to show Pi-dependent MGP upregulation.","method":"Chromatin immunoprecipitation, in vitro DNA binding assay, MEK inhibitor (U0126), Fra-1-deficient mouse primary osteoblasts, siRNA knockdown","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus genetic knockout confirmation plus pharmacological inhibition, multiple orthogonal methods","pmids":["19419315"],"is_preprint":false},{"year":2010,"finding":"Fra-1 binds to the interleukin-6 (IL-6) promoter in macrophages to increase IL-6 production. IL-6 then acts in an autocrine fashion to skew macrophage differentiation into M2d macrophages. Fra-1 overexpression is induced in macrophages by tumor cell co-culture.","method":"ChIP assay, co-culture experiments, IL-6 promoter binding analysis, macrophage differentiation assay","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and functional co-culture assay, single lab","pmids":["20386569"],"is_preprint":false},{"year":2010,"finding":"Heterodimerization of Fra-1 with c-Jun stabilizes c-Jun in RAS-transformed cells. ERK pathway activity and Fra-1/c-Jun heterodimerization cooperate to prevent c-Jun proteasomal breakdown; phosphorylation of the Fra-1 C-terminal domain (which controls Fra-1 stability in response to ERK signaling) is required for this stabilizing effect on c-Jun.","method":"Co-immunoprecipitation, protein half-life analysis, ERK inhibitor treatment, constitutively transformed thyroid cell lines, dimerization-deficient Fra-1 mutants","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted mechanism with mutagenesis, reciprocal Co-IP, and pharmacological dissection in same study","pmids":["20543861"],"is_preprint":false},{"year":2011,"finding":"FOSL1 is a downstream effector of the PI3K/AKT signaling pathway in trophoblast cells. Nuclear FOSL1 increases during trophoblast differentiation in a PI3K/AKT-dependent manner. FOSL1 occupies the Mmp9 promoter in trophoblast cells (ChIP) and regulates Mmp9 expression; knockdown of FOSL1 abrogates trophoblast invasion in vitro and in vivo (lentiviral shRNA).","method":"PI3K/AKT inhibitors, AKT isoform-specific siRNA, ChIP, lentiviral shRNA in vivo, trophoblast invasion assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus in vivo lentiviral KD with invasion readout, multiple orthogonal methods","pmids":["21947281"],"is_preprint":false},{"year":2011,"finding":"Fra-1 directly suppresses the adipogenic transcription factor C/EBPα (Cebpa) by binding to the Cebpa promoter, thereby autonomously blocking adipocyte differentiation. Fra-1 transgenic mice develop severe lipodystrophy with reduced adipogenic markers; Fra-1 overexpression in adipogenic cell lines blocks their differentiation.","method":"Fra-1 transgenic mice, primary transgenic osteoblast adipogenic differentiation assay, promoter binding/ChIP assay, adipogenic cell line overexpression","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus transgenic mouse plus cell-autonomous differentiation assay","pmids":["21486951"],"is_preprint":false},{"year":2012,"finding":"Fra-1 preferentially associates with c-Jun and binds to the promoter regions of the cyclin-dependent kinase inhibitor genes p21 (Cdkn1a) and p16 (Cdkn2a), leading to their transcriptional upregulation and induction of vascular senescence phenotypes in response to angiotensin II.","method":"Co-immunoprecipitation (Fra-1/c-Jun interaction), chromatin immunoprecipitation (p21 and p16 promoters), Fra-1 siRNA knockdown, senescence-associated β-galactosidase assay, in vivo Ang II infusion model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus in vivo model, single lab","pmids":["30892941"],"is_preprint":false},{"year":2012,"finding":"Fra-1 directly regulates MMP-9 expression in rhinovirus-infected bronchial epithelial cells. AP-1 sites in the MMP-9 promoter are required for HRV-induced MMP-9 promoter drive; EMSA/supershift identified Fra-1 in AP-1 complexes bound to the MMP-9 promoter; siRNA knockdown of Fra-1 abolished MMP-9 expression. MEK1/2 inhibition reduced Fra-1 expression and MMP-9. Formoterol and dexamethasone suppress Fra-1 and MMP-9 via reduced ERK phosphorylation.","method":"Site-directed mutagenesis of AP-1 sites, EMSA with supershift, siRNA knockdown, MEK inhibitors, pharmacological treatment","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA/supershift plus siRNA with multiple confirmatory approaches, single lab","pmids":["22461694"],"is_preprint":false},{"year":2012,"finding":"Estrogen receptor α (ESR1) directly recruits to an estrogen response element in the Fra-1 promoter (demonstrated by ChIP), regulating Fra-1 expression in uterine stromal cells. Fra-1 in turn controls MMP9 and MMP13 expression critical for stromal extracellular matrix remodeling during decidualization. Fra-1 knockdown during in vitro decidualization blocks stromal differentiation and cell migration.","method":"ChIP (ESR1 binding to Fra-1 promoter), siRNA-mediated ESR1 silencing, Fra-1 knockdown, in vitro decidualization assay, migration assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus siRNA knockdown with differentiation/migration readout, single lab","pmids":["22514284"],"is_preprint":false},{"year":2014,"finding":"Fra-1 induces EMT in mammary epithelial cells by directly binding to the tgfb1 and zeb2 promoters and to an evolutionarily conserved region in the first intron of zeb1, increasing expression of TGFβ1, Zeb1, Zeb2, and Slug. Silencing of zeb1 or zeb2 (but not TGFβ inhibition alone) fully restored epithelial phenotype and decreased invasion, placing Zeb1/Zeb2 downstream of Fra-1 in EMT.","method":"ChIP (Fra-1 binding to tgfb1, zeb1, zeb2 loci), luciferase reporter assays, siRNA knockdown, ectopic Fra-1 expression in EpH4 cells, in vivo transplantation","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus reporter assays plus genetic epistasis (siRNA rescue) plus in vivo tumor model, multiple methods","pmids":["25301070"],"is_preprint":false},{"year":2014,"finding":"Fra-1 controls transcription of the uPA/Plau gene in metastatic breast cancer cells via binding to two AP-1 enhancers (ABR-1.9 and ABR-4.1, located ~1.9 and ~4.1 kb upstream of the TSS), promoting RNA Pol II recruitment and productive transcription of Plau-001 mRNA; Fra-1 also tempers expression of a minor Plau-004 transcript from ABR-1.9.","method":"ChIP, pharmacological inhibition, RNAi, RNA Pol II ChIP, chromosome conformation capture (3C)","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP, 3C, and RNAi combined with transcriptional run-on; multiple orthogonal methods","pmids":["25200076"],"is_preprint":false},{"year":2017,"finding":"FOSL1 is a negative regulator of type I interferon (IFN-I) signaling. Upon stimulation with poly(I:C), malaria-infected RBCs, or VSV, FOSL1 translocates from the nucleus to the cytoplasm where it inhibits interactions between TRAF3, TRIF, and TBK1 by impairing K63-linked polyubiquitination of TRAF3 and TRIF. FOSL1 knockout chimeric mice show lower parasitemia/viral titers and decreased mortality.","method":"Co-immunoprecipitation (TRAF3/TRIF/TBK1 interactions), ubiquitination assays, FOSL1 knockout chimeric mice, cellular fractionation/localization, poly(I:C) and viral stimulation","journal":"mBio","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical mechanism (ubiquitination + protein interactions) validated in vivo with KO mice, multiple orthogonal methods","pmids":["28049150"],"is_preprint":false},{"year":2017,"finding":"FOSL1 is the main immediate-early AP-1 member induced by melanoma oncogenes and acts oncogenically by transcriptionally activating HMGA1. FOSL1 transforms melanocytes, downregulates MITF in a HMGA1-dependent manner, upregulates AXL, and re-enforces MYC, E2F3, and AP-1, enabling subcutaneous tumor growth in vivo. HMGA1 mediates FOSL1-driven migration, proliferation, and anoikis-independent growth.","method":"siRNA knockdown, ectopic expression, in vivo melanocyte transformation assay, gene expression profiling, promoter analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with in vivo transformation and mechanistic epistasis (HMGA1 dependence), single lab","pmids":["28481878"],"is_preprint":false},{"year":2017,"finding":"MLK3 kinase drives invasion in TNBC cells through FRA-1: MLK3 expression robustly upregulates FRA-1 in breast cancer cells, accompanied by elevation of MMP-1 and MMP-9; FRA-1 silencing abrogates MLK3-induced invasion. MLK3 depletion (siRNA or CRISPR) significantly reduces FRA-1 and MMP-1/MMP-9 levels and decreases transendothelial migration.","method":"Inducible MLK3 expression, FRA-1 siRNA, CRISPR/Cas9n MLK3 deletion, invasion assay, transendothelial migration assay, MMP expression","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established with both siRNA and CRISPR, single lab","pmids":["28604765"],"is_preprint":false},{"year":2018,"finding":"Integrin αVβ3/uPAR signaling leads to FAK-SRC-ERK2-mediated phosphorylation and stabilization of FRA-1, enhancing breast cancer invasion on vitronectin. Transient knockdown of uPAR reduces FRA-1 phosphorylation and stabilization; both uPAR and FRA-1 are required for vitronectin-induced invasion.","method":"Pharmacological inhibitors (FAK, SRC, ERK), uPAR siRNA knockdown, FRA-1 phosphorylation immunoblot, invasion assay on vitronectin","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection plus siRNA epistasis with mechanistic phosphorylation readout, single lab","pmids":["29382358"],"is_preprint":false},{"year":2019,"finding":"Fra-1 directly binds to the arginase-1 (Arg1) promoter in macrophages (demonstrated by ChIP-seq and standard ChIP) and transcriptionally represses Arg1 expression. Macrophage-specific Fra-1-deficient mice show enhanced Arg1 expression/activity and reduced arthritis severity; the phenotype is reversed by arginase inhibition, placing Fra-1 upstream of Arg1 in macrophage inflammatory regulation.","method":"ChIP-seq, standard ChIP, luciferase reporter assay, macrophage-specific conditional Fra-1 KO mice, arginase inhibitor treatment, arthritis model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP-seq plus ChIP plus reporter assay plus conditional KO mouse with pharmacological rescue, multiple orthogonal methods","pmids":["30990796"],"is_preprint":false},{"year":2019,"finding":"Fra-1 directly regulates HMGA1 gene transcription in TNBC cells by binding to enhancer elements in the last two introns of HMGA1. Fra-1 binding is required for RNA Polymerase II recruitment at the HMGA1 promoter through pre-existing chromatin loops linking intragenic enhancers to the promoter; Fra-1 is not required for chromatin loop formation but exploits pre-existing interactions.","method":"ChIP, RNAi, transcriptional run-on assay, chromosome conformation capture (3C), mRNA analysis","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus 3C plus transcriptional run-on with RNAi validation, multiple orthogonal methods","pmids":["31300541"],"is_preprint":false},{"year":2019,"finding":"PARP1 interacts with and downregulates Fra-1, reducing AP-1 transcriptional activity. Olaparib treatment or PARP1 silencing increases Fra-1 levels and AP-1 transcriptional activity. A large fraction of PARP1-regulated genes was dependent on Fra-1, as established by large-scale chromatin-bound Fra-1 proteomics screen identifying PARP1 among 118 Fra-1-interacting proteins.","method":"Co-immunoprecipitation (endogenous Fra-1-PARP1), AP-1 reporter assays, PARP1 inhibitor (olaparib), PARP1 siRNA, proteomic screen of chromatin-bound Fra-1","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional reporter assay plus pharmacological and genetic perturbation, single lab","pmids":["33652085"],"is_preprint":false},{"year":2021,"finding":"FOSL1 promotes HNSCC metastasis predominantly through selective association with Mediator complex components to establish super-enhancers (SEs) at cancer stemness and pro-metastatic genes including SNAI2 and FOSL1 itself. Depletion of FOSL1 disrupts SEs and inhibits expression of these oncogenes.","method":"ChIP-seq for SE analysis, Mediator co-association assay, FOSL1 knockdown, patient-derived xenograft model, spontaneous mouse model","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus in vivo PDX model, single lab","pmids":["33794365"],"is_preprint":false},{"year":2021,"finding":"FOSL1 promotes proneural-to-mesenchymal transition (PMT) in glioblastoma stem cells via UBC9-dependent CYLD SUMOylation. FOSL1 facilitates UBC9-mediated SUMOylation of CYLD, inducing K63-linked polyubiquitination of NF-κB intermediaries and NF-κB activation, which drives PMT.","method":"siRNA knockdown, ectopic expression, SUMOylation assay, ubiquitination assay, NF-κB reporter, in vivo tumor-initiating assay","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical mechanism (SUMOylation/ubiquitination) with functional rescue, single lab","pmids":["35351656"],"is_preprint":false},{"year":2021,"finding":"Fosl1 interacts with JunB and promotes expression of Cyclin-T1 (Ccnt1) during heart regeneration, driving cardiomyocyte proliferation. Demonstrated by Co-immunoprecipitation (Fosl1/JunB interaction), luciferase reporter assays, and ChIP analysis. Cardiomyocyte-specific dominant-negative Fosl1 impairs cardiomyocyte proliferation in X. tropicalis; Fosl1 knockdown suppresses neonatal mouse heart regeneration while overexpression improves cardiac function after myocardial infarction.","method":"Co-immunoprecipitation, luciferase reporter assay, ChIP, cardiomyocyte-specific dominant-negative transgene, siRNA knockdown, in vivo heart injury models","journal":"NPJ Regenerative medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus multiple in vivo models, single lab","pmids":["34188056"],"is_preprint":false},{"year":2021,"finding":"SMAD4 represses FOSL1 expression, and FOSL1 is sufficient to drive metastatic colonization to the lung as identified in an in vivo genetic screen using isogenic SMAD4-deleted pancreatic cancer cell lines.","method":"Isogenic SMAD4 cell lines, in vivo metastasis screen, FOSL1 overexpression","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo functional screen with isogenic lines establishing pathway position, single lab","pmids":["34320363"],"is_preprint":false},{"year":2022,"finding":"FOSL1 binds to the Klotho promoter (demonstrated by ChIP enrichment) and preserves Klotho expression during acute kidney injury. Selective Fosl1 deficiency in proximal tubular cells (Fosl1Δtub) worsens AKI, reduces Klotho, and increases NF-κB/AP-1 activity; recombinant Klotho administration rescues Fosl1Δtub mice from cisplatin-AKI, placing Klotho downstream of Fosl1.","method":"ChIP (Fosl1 binding to Klotho promoter), conditional tubular-specific Fosl1 KO mice, cisplatin/folate AKI models, recombinant Klotho rescue","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus conditional KO mouse plus pharmacological rescue establishing pathway position","pmids":["36565807"],"is_preprint":false},{"year":2022,"finding":"FOSL1 and FOSL2 co-repress Th17 fate-specification in human T cells, contrasting with BATF which promotes the Th17 lineage. Genome-wide binding analysis revealed FOSL1, FOSL2, and BATF share occupancy over regulatory regions of Th17 commitment genes and share protein-interacting partners, suggesting a competitive mechanism.","method":"Genome-wide ChIP-seq binding analysis, siRNA-mediated knockdown, Th17 differentiation assay, protein interaction mapping","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus functional differentiation assay, single lab","pmids":["35511484"],"is_preprint":false},{"year":2022,"finding":"FOSL1 positively regulates DUSP7 transcription in doxorubicin-resistant breast cancer cells, and DUSP7 promotes dephosphorylation of PEA15, enhancing drug resistance. This FOSL1/DUSP7/PEA15 pathway was established by ChIP (FOSL1 binding to DUSP7 promoter) and functional rescue experiments.","method":"ChIP (FOSL1 binding to DUSP7 promoter), siRNA knockdown, overexpression, in vitro and in vivo drug resistance assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional rescue, single lab","pmids":["34907034"],"is_preprint":false},{"year":2022,"finding":"FOSL1 deacetylation at Lys-116 within its DNA binding domain increases its transcriptional activity. TRPM7 induces FOSL1 transcriptional activation via STAT3, which binds to GAS elements at -328 to -336 and -378 to -386 in the FOSL1 promoter (confirmed by ChIP-qPCR). FOSL1 promotes glioma stem cell marker expression and maintains stem cell activity.","method":"Luciferase reporter with GAS element mutants, ChIP-qPCR, constitutively active/dominant-negative STAT3, FOSL1 acetylation/deacetylation assay","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR plus reporter mutagenesis plus PTM identification, single lab","pmids":["37642779"],"is_preprint":false},{"year":2023,"finding":"CYTOR (a nuclear lncRNA) facilitates formation of FOSL1 phase-separated condensates and FOSL1-dependent super-enhancers to drive cancer stemness and pro-metastatic gene expression in HNSCC tumor budding cells. In turn, FOSL1 activation promotes CYTOR transcription, forming a feedback loop. Depletion of CYTOR disrupts FOSL1-dependent SEs.","method":"Phase separation assay, ChIP-seq for SE analysis, CYTOR/FOSL1 knockdown, in vivo tumor growth and lymph node metastasis model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phase separation assay plus ChIP-seq plus in vivo model, single lab","pmids":["38032139"],"is_preprint":false},{"year":2023,"finding":"CAF-derived exosomal FOSL1 is transferred to colorectal cancer cells and transcriptionally activates ITGB4 (integrin β4), promoting CRC cell proliferation, stemness, and oxaliplatin resistance. Transcriptional activation of ITGB4 by FOSL1 was confirmed by ChIP and dual-luciferase reporter assays.","method":"Exosome isolation, ChIP assay, dual-luciferase reporter assay, FOSL1 overexpression/knockdown, co-culture with CAF-conditioned medium, exosome inhibitor GW4869","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus exosome transfer experiment, single lab","pmids":["37160555"],"is_preprint":false},{"year":2025,"finding":"FOSL1 transcriptionally activates glycolytic genes SLC2A1, ENO1, and LDHA in TNBC cells, enhancing the Warburg effect. FOSL1 promotes tumor growth in a glycolysis-dependent manner (2-DG abolishes FOSL1 oncogenic effects). Established by ChIP and luciferase reporter assays.","method":"ChIP, luciferase reporter assay, glucose uptake/lactate/ECAR measurements, 2-DG inhibition, xenograft model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus metabolic rescue experiment, single lab","pmids":["39748430"],"is_preprint":false}],"current_model":"FOSL1/FRA-1 is a FOS-family bZIP transcription factor that heterodimerizes with JUN partners to form AP-1 complexes; it lacks classical transactivation domains but is oncogenically activated downstream of RAS-RAF-MEK-ERK signaling (and PI3K/AKT), which phosphorylates and stabilizes the protein via MEK/ERK-dependent posttranslational mechanisms. Fra-1 accumulation is maintained by transcriptional autoregulation through an AP-1 site in its first intron. It drives invasion, EMT, and metastasis by directly binding to and activating promoters/enhancers of target genes including ZEB1, ZEB2, TGFβ1, MMP-1, MMP-9, HMGA1, ITGB4, SLC2A1, ENO1, and LDHA, and represses genes such as Arg1 and C/EBPα; it also assembles super-enhancers via Mediator association. Beyond nuclear transcription, Fra-1 translocates to the cytoplasm upon innate immune stimulation where it blocks TRAF3/TRIF/TBK1 interactions to suppress type I interferon responses. Fra-1 additionally stabilizes its dimerization partner c-Jun through an ERK-dependent heterodimerization mechanism."},"narrative":{"mechanistic_narrative":"FOSL1 (FRA-1) is a serum-inducible immediate-early FOS-family bZIP transcription factor that, despite lacking classical transactivation domains, functions as an AP-1 component to drive tumor invasion, epithelial-to-mesenchymal transition, and metastasis [PMID:3133553, PMID:9819396, PMID:25301070]. Its accumulation in oncogenically transformed cells is established by a dual mechanism: transcriptional autoregulation through an AP-1 site in its own first intron, and RAS-MEK/ERK-dependent posttranslational stabilization that markedly extends protein half-life [PMID:7791782, PMID:12773579]; this stabilization depends on an intact ERK phosphorylation site, and analogous MEK5-ERK5 phosphorylation and integrin αVβ3/uPAR–FAK-SRC-ERK2 signaling converge to control FRA-1 activity and turnover [PMID:11756554, PMID:12622723, PMID:29382358]. FRA-1 transactivation requires heterodimerization with JUN-family partners, and FRA-1/c-Jun heterodimerization reciprocally stabilizes c-Jun in an ERK-dependent manner [PMID:12773579, PMID:20543861]. As a sequence-specific factor it directly binds promoters and intragenic/enhancer elements to activate a pro-invasive and pro-metastatic program, including the EMT regulators ZEB1, ZEB2, and TGFβ1, the matrix protease genes MMP-1, MMP-9, and PLAU/uPA, the oncogene HMGA1, integrin ITGB4, and the glycolytic genes SLC2A1, ENO1, and LDHA, while repressing differentiation genes such as C/EBPα and the macrophage gene Arg1 [PMID:21486951, PMID:25301070, PMID:25200076, PMID:30990796, PMID:31300541, PMID:39748430]. FRA-1 frequently exploits pre-existing chromatin loops to recruit RNA Polymerase II and assembles Mediator-associated super-enhancers at stemness and pro-metastatic loci [PMID:31300541, PMID:33794365]. Genetically, FRA-1 can substitute for c-Fos in vivo, rescuing osteopetrosis in c-fos-mutant mice, and acts as a limiting factor for osteoclast differentiation [PMID:10199556, PMID:10655067]. Beyond cancer it has tissue-protective and immunoregulatory roles: it preserves Klotho during acute kidney injury, drives cardiomyocyte proliferation during heart regeneration via JunB, and acts as a negative regulator of type I interferon signaling by translocating to the cytoplasm to block TRAF3/TRIF/TBK1 assembly [PMID:28049150, PMID:34188056, PMID:36565807].","teleology":[{"year":1988,"claim":"Established FRA-1 as a distinct FOS-family immediate-early gene, answering whether the Fos-related antigen was an independent serum-responsive regulator rather than a c-Fos artifact.","evidence":"cDNA cloning, sequencing, and Northern analysis of serum-stimulated rat fibroblasts","pmids":["3133553"],"confidence":"High","gaps":["Did not define DNA-binding specificity or dimer partners","No functional role assigned"]},{"year":1995,"claim":"Showed FRA-1 is oncogenic and autoregulated despite lacking a classical transactivation domain, reframing how a transactivation-deficient factor could transform cells.","evidence":"Intron mutagenesis, Gal4-fusion transactivation assays, soft-agar and nude-mouse tumorigenesis","pmids":["7791782"],"confidence":"High","gaps":["Mechanism of transactivation-independent transformation not resolved","Required dimer partner unidentified"]},{"year":1998,"claim":"Demonstrated a direct causal role for FRA-1 in epithelial-to-mesenchymal-like conversion and invasion, linking it to late-stage tumor progression.","evidence":"Retroviral FRA-1 expression in CSML0 carcinoma cells with invasion, morphology, and EMSA readouts","pmids":["9819396"],"confidence":"High","gaps":["Direct target genes of the EMT program not yet identified"]},{"year":2000,"claim":"Genetic rescue experiments established FRA-1 as a functional in vivo substitute for c-Fos and a RANKL/c-Fos-driven effector in osteoclast differentiation.","evidence":"Retroviral rescue and transgenic rescue of c-fos-null osteopetrosis, in vitro osteoclast assays (also [#3])","pmids":["10655067","10199556"],"confidence":"High","gaps":["Target genes downstream of FRA-1 in osteoclasts not defined"]},{"year":2003,"claim":"Resolved how FRA-1 accumulates in transformed cells, establishing combined intronic autoregulation and MEK/ERK-dependent protein stabilization as the basis for RAS-driven accumulation.","evidence":"ChIP, MEK inhibition, protein half-life and reporter assays in ras-transformed cells; ERK-site mutagenesis (also [#5, #7])","pmids":["12773579","11756554","12622723"],"confidence":"High","gaps":["Identity of the obligate heterodimer partner in transformed cells not pinned down here","ERK5 versus ERK1/2 site contributions only partially separated"]},{"year":2010,"claim":"Defined a reciprocal regulatory mechanism by which FRA-1/c-Jun heterodimerization stabilizes c-Jun, coupling FRA-1 stability and dimerization to AP-1 output.","evidence":"Co-IP, protein half-life, ERK inhibition, and dimerization-deficient FRA-1 mutants in transformed thyroid cells","pmids":["20543861"],"confidence":"High","gaps":["Degradation machinery for c-Jun in this context not fully defined","Ubiquitin-independent versus -dependent turnover of FRA-1 itself only partly characterized ([#11])"]},{"year":2014,"claim":"Identified the direct transcriptional targets through which FRA-1 enforces EMT, placing ZEB1/ZEB2 epistatically downstream of FRA-1.","evidence":"ChIP at tgfb1/zeb1/zeb2 loci, reporter assays, siRNA epistasis, and in vivo transplantation (with PLAU enhancer mapping in [#21])","pmids":["25301070","25200076"],"confidence":"High","gaps":["Selectivity of FRA-1 among AP-1 dimers at these loci not fully resolved"]},{"year":2017,"claim":"Revealed a non-transcriptional, cytoplasmic function for FOSL1 as a negative regulator of type I interferon signaling, expanding its role beyond nuclear AP-1.","evidence":"Co-IP of TRAF3/TRIF/TBK1, ubiquitination assays, fractionation, and FOSL1-KO chimeric mice challenged with poly(I:C)/virus/malaria","pmids":["28049150"],"confidence":"High","gaps":["Signal triggering nuclear-to-cytoplasmic translocation not defined","Structural basis of TRAF3/TRIF interference unknown"]},{"year":2019,"claim":"Showed FRA-1 acts on chromatin via pre-existing loops and ChIP-seq-scale target programs, including transcriptional repression of Arg1 in macrophages.","evidence":"ChIP-seq, 3C, transcriptional run-on, conditional macrophage Fra-1 KO with arginase rescue (also HMGA1 enhancer looping in [#27])","pmids":["30990796","31300541"],"confidence":"High","gaps":["Determinants of activator versus repressor behavior at different loci unresolved"]},{"year":2021,"claim":"Connected FOSL1 to super-enhancer assembly and tissue-protective/regenerative roles, broadening its mechanism to Mediator co-association and condensate formation.","evidence":"ChIP-seq super-enhancer mapping with Mediator co-association in HNSCC, JunB Co-IP/ChIP in heart regeneration, and SMAD4-repression metastasis screen (also [#37, #33])","pmids":["33794365","34188056","34320363"],"confidence":"Medium","gaps":["Mediator-selectivity mechanism not biochemically dissected","Single-lab models for each tissue context"]},{"year":2022,"claim":"Extended the FOSL1 target program to metabolic reprogramming and post-translational/upstream control, including STAT3-driven induction and DNA-binding-domain acetylation.","evidence":"ChIP and reporter assays for glycolytic genes (SLC2A1/ENO1/LDHA) with 2-DG rescue, plus STAT3/TRPM7 and Lys-116 deacetylation studies (also [#33, #38])","pmids":["39748430","37642779","36565807"],"confidence":"Medium","gaps":["Enzymes controlling Lys-116 acetylation not identified","Many target programs validated in single cell systems"]},{"year":null,"claim":"How FOSL1 selects among AP-1 dimer partners and target loci to switch between activator, repressor, super-enhancer-organizing, and cytoplasmic IFN-suppressing roles remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking phosphorylation/acetylation state to partner choice and locus selection","Signal governing nuclear-cytoplasmic partitioning undefined","Structural basis of transactivation-domain-independent activity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,16,20,21,26,27,39]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,12,20,26,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,15,20,27]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,20,21,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,8,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,20,29,39]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[22,26,34]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,16,20,31]}],"complexes":["AP-1","Mediator-associated super-enhancer"],"partners":["JUN","JUNB","STAT3","PARP1","TRAF3","MED (MEDIATOR)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P15407","full_name":"Fos-related antigen 1","aliases":[],"length_aa":271,"mass_kda":29.4,"function":"","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P15407/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOSL1","classification":"Not Classified","n_dependent_lines":386,"n_total_lines":1208,"dependency_fraction":0.3195364238410596},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOSL1","total_profiled":1310},"omim":[{"mim_id":"615093","title":"LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS K; LY6K","url":"https://www.omim.org/entry/615093"},{"mim_id":"608455","title":"GLYCOGEN PHOSPHORYLASE, MUSCLE; PYGM","url":"https://www.omim.org/entry/608455"},{"mim_id":"601990","title":"TUMOR PROTEIN p73; TP73","url":"https://www.omim.org/entry/601990"},{"mim_id":"601516","title":"SPLICING FACTOR 1; SF1","url":"https://www.omim.org/entry/601516"},{"mim_id":"601442","title":"COFILIN 1; CFL1","url":"https://www.omim.org/entry/601442"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":51.3},{"tissue":"urinary bladder","ntpm":78.4}],"url":"https://www.proteinatlas.org/search/FOSL1"},"hgnc":{"alias_symbol":["fra-1"],"prev_symbol":[]},"alphafold":{"accession":"P15407","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15407","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15407-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15407-F1-predicted_aligned_error_v6.png","plddt_mean":65.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOSL1","jax_strain_url":"https://www.jax.org/strain/search?query=FOSL1"},"sequence":{"accession":"P15407","fasta_url":"https://rest.uniprot.org/uniprotkb/P15407.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15407/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15407"}},"corpus_meta":[{"pmid":"3133553","id":"PMC_3133553","title":"fra-1: a serum-inducible, cellular immediate-early gene that encodes a fos-related antigen.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3133553","citation_count":573,"is_preprint":false},{"pmid":"10655067","id":"PMC_10655067","title":"Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10655067","citation_count":279,"is_preprint":false},{"pmid":"23001043","id":"PMC_23001043","title":"MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23001043","citation_count":191,"is_preprint":false},{"pmid":"20386569","id":"PMC_20386569","title":"Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20386569","citation_count":183,"is_preprint":false},{"pmid":"9819396","id":"PMC_9819396","title":"Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9819396","citation_count":170,"is_preprint":false},{"pmid":"7791782","id":"PMC_7791782","title":"Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7791782","citation_count":160,"is_preprint":false},{"pmid":"25301070","id":"PMC_25301070","title":"Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25301070","citation_count":131,"is_preprint":false},{"pmid":"19419315","id":"PMC_19419315","title":"Phosphate-dependent regulation of MGP in osteoblasts: role of ERK1/2 and Fra-1.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19419315","citation_count":122,"is_preprint":false},{"pmid":"16784822","id":"PMC_16784822","title":"Fra-1 a target for cancer prevention or intervention.","date":"2006","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16784822","citation_count":109,"is_preprint":false},{"pmid":"11756554","id":"PMC_11756554","title":"Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11756554","citation_count":106,"is_preprint":false},{"pmid":"12622723","id":"PMC_12622723","title":"Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway.","date":"2003","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/12622723","citation_count":90,"is_preprint":false},{"pmid":"12773579","id":"PMC_12773579","title":"Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12773579","citation_count":89,"is_preprint":false},{"pmid":"33794365","id":"PMC_33794365","title":"FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33794365","citation_count":87,"is_preprint":false},{"pmid":"26975631","id":"PMC_26975631","title":"SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26975631","citation_count":84,"is_preprint":false},{"pmid":"34399888","id":"PMC_34399888","title":"NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34399888","citation_count":82,"is_preprint":false},{"pmid":"35163444","id":"PMC_35163444","title":"Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163444","citation_count":78,"is_preprint":false},{"pmid":"28481878","id":"PMC_28481878","title":"The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28481878","citation_count":75,"is_preprint":false},{"pmid":"17572495","id":"PMC_17572495","title":"Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17572495","citation_count":71,"is_preprint":false},{"pmid":"30990796","id":"PMC_30990796","title":"Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30990796","citation_count":70,"is_preprint":false},{"pmid":"35351656","id":"PMC_35351656","title":"FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-κB axis.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35351656","citation_count":67,"is_preprint":false},{"pmid":"21947281","id":"PMC_21947281","title":"FOSL1 is integral to establishing the maternal-fetal interface.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21947281","citation_count":67,"is_preprint":false},{"pmid":"25381818","id":"PMC_25381818","title":"FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25381818","citation_count":63,"is_preprint":false},{"pmid":"31672492","id":"PMC_31672492","title":"The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31672492","citation_count":63,"is_preprint":false},{"pmid":"32385348","id":"PMC_32385348","title":"The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32385348","citation_count":62,"is_preprint":false},{"pmid":"29384218","id":"PMC_29384218","title":"microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29384218","citation_count":62,"is_preprint":false},{"pmid":"28604746","id":"PMC_28604746","title":"Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28604746","citation_count":59,"is_preprint":false},{"pmid":"24084233","id":"PMC_24084233","title":"Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration.","date":"2013","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/24084233","citation_count":56,"is_preprint":false},{"pmid":"32199129","id":"PMC_32199129","title":"Silencing lncRNA AGAP2-AS1 Upregulates miR-195-5p to Repress Migration and Invasion of EC Cells via the Decrease of FOSL1 Expression.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32199129","citation_count":53,"is_preprint":false},{"pmid":"21969367","id":"PMC_21969367","title":"Molecular characterization of the microRNA-138-Fos-like antigen 1 (FOSL1) regulatory module in squamous cell carcinoma.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21969367","citation_count":52,"is_preprint":false},{"pmid":"35326630","id":"PMC_35326630","title":"The Fra-1/AP-1 Oncoprotein: From the \"Undruggable\" Transcription Factor to Therapeutic Targeting.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35326630","citation_count":51,"is_preprint":false},{"pmid":"14519134","id":"PMC_14519134","title":"Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter.","date":"2003","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14519134","citation_count":47,"is_preprint":false},{"pmid":"28604765","id":"PMC_28604765","title":"MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.","date":"2017","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28604765","citation_count":46,"is_preprint":false},{"pmid":"21640141","id":"PMC_21640141","title":"Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosarcoma cells.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21640141","citation_count":46,"is_preprint":false},{"pmid":"29112457","id":"PMC_29112457","title":"FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29112457","citation_count":45,"is_preprint":false},{"pmid":"17254320","id":"PMC_17254320","title":"FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders.","date":"2007","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17254320","citation_count":45,"is_preprint":false},{"pmid":"21486951","id":"PMC_21486951","title":"Elevated Fra-1 expression causes severe lipodystrophy.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21486951","citation_count":44,"is_preprint":false},{"pmid":"11106247","id":"PMC_11106247","title":"FRA-1 expression in hyperplastic and neoplastic thyroid diseases.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11106247","citation_count":44,"is_preprint":false},{"pmid":"33887357","id":"PMC_33887357","title":"FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.","date":"2021","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33887357","citation_count":43,"is_preprint":false},{"pmid":"27685628","id":"PMC_27685628","title":"The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27685628","citation_count":43,"is_preprint":false},{"pmid":"32305558","id":"PMC_32305558","title":"ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32305558","citation_count":43,"is_preprint":false},{"pmid":"17825471","id":"PMC_17825471","title":"Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?","date":"2007","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/17825471","citation_count":43,"is_preprint":false},{"pmid":"31665243","id":"PMC_31665243","title":"EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31665243","citation_count":43,"is_preprint":false},{"pmid":"35298069","id":"PMC_35298069","title":"Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35298069","citation_count":42,"is_preprint":false},{"pmid":"25200076","id":"PMC_25200076","title":"Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25200076","citation_count":41,"is_preprint":false},{"pmid":"28049150","id":"PMC_28049150","title":"FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions.","date":"2017","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/28049150","citation_count":40,"is_preprint":false},{"pmid":"34320363","id":"PMC_34320363","title":"SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34320363","citation_count":39,"is_preprint":false},{"pmid":"16490785","id":"PMC_16490785","title":"A Phosphatidylinositol 3-kinase-regulated Akt-independent signaling promotes cigarette smoke-induced FRA-1 expression.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16490785","citation_count":37,"is_preprint":false},{"pmid":"22364734","id":"PMC_22364734","title":"Intermittent hypoxia and systemic leptin administration induces pSTAT3 and Fos/Fra-1 in the carotid body.","date":"2012","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22364734","citation_count":37,"is_preprint":false},{"pmid":"37176013","id":"PMC_37176013","title":"FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37176013","citation_count":35,"is_preprint":false},{"pmid":"22911824","id":"PMC_22911824","title":"Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22911824","citation_count":33,"is_preprint":false},{"pmid":"35292358","id":"PMC_35292358","title":"LncRNA HOTAIR sponges miR-301a-3p to promote glioblastoma proliferation and invasion through upregulating FOSL1.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35292358","citation_count":33,"is_preprint":false},{"pmid":"36565807","id":"PMC_36565807","title":"The transcription factor Fosl1 preserves Klotho expression and protects from acute kidney injury.","date":"2022","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/36565807","citation_count":32,"is_preprint":false},{"pmid":"33450386","id":"PMC_33450386","title":"FOSL1 promotes tumorigenesis in colorectal carcinoma by mediating the FBXL2/Wnt/β-catenin axis via Smurf1.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/33450386","citation_count":32,"is_preprint":false},{"pmid":"29382358","id":"PMC_29382358","title":"Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.","date":"2018","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/29382358","citation_count":32,"is_preprint":false},{"pmid":"15714138","id":"PMC_15714138","title":"RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium.","date":"2005","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/15714138","citation_count":31,"is_preprint":false},{"pmid":"35511484","id":"PMC_35511484","title":"A systematic comparison of FOSL1, FOSL2 and BATF-mediated transcriptional regulation during early human Th17 differentiation.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35511484","citation_count":30,"is_preprint":false},{"pmid":"32661324","id":"PMC_32661324","title":"AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32661324","citation_count":30,"is_preprint":false},{"pmid":"34309413","id":"PMC_34309413","title":"Saikosaponin-d Alleviates Renal Inflammation and Cell Apoptosis in a Mouse Model of Sepsis via TCF7/FOSL1/Matrix Metalloproteinase 9 Inhibition.","date":"2021","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34309413","citation_count":30,"is_preprint":false},{"pmid":"38032139","id":"PMC_38032139","title":"CYTOR Facilitates Formation of FOSL1 Phase Separation and Super Enhancers to Drive Metastasis of Tumor Budding Cells in Head and Neck Squamous Cell Carcinoma.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38032139","citation_count":28,"is_preprint":false},{"pmid":"34282187","id":"PMC_34282187","title":"The role of FOSL1 in stem-like cell reprogramming processes.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34282187","citation_count":28,"is_preprint":false},{"pmid":"30563891","id":"PMC_30563891","title":"Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30563891","citation_count":28,"is_preprint":false},{"pmid":"11953459","id":"PMC_11953459","title":"Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal apoptosis.","date":"2002","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11953459","citation_count":27,"is_preprint":false},{"pmid":"20543861","id":"PMC_20543861","title":"Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20543861","citation_count":27,"is_preprint":false},{"pmid":"32753701","id":"PMC_32753701","title":"FOSL1 is a novel mediator of endotoxin/lipopolysaccharide-induced pulmonary angiogenic signaling.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32753701","citation_count":26,"is_preprint":false},{"pmid":"34992218","id":"PMC_34992218","title":"NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34992218","citation_count":26,"is_preprint":false},{"pmid":"36032067","id":"PMC_36032067","title":"The Fra-1: Novel role in regulating extensive immune cell states and affecting inflammatory diseases.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36032067","citation_count":25,"is_preprint":false},{"pmid":"31932373","id":"PMC_31932373","title":"Characterization of FosL1, a Plasmid-Encoded Fosfomycin Resistance Protein Identified in Escherichia coli.","date":"2020","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31932373","citation_count":25,"is_preprint":false},{"pmid":"10199556","id":"PMC_10199556","title":"Fra-1 potentiates osteoclastic differentiation in osteoclast-macrophage precursor cell lines.","date":"1999","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10199556","citation_count":25,"is_preprint":false},{"pmid":"21480331","id":"PMC_21480331","title":"Transcription factor Fra-1 induces cholangitis and liver fibrosis.","date":"2011","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21480331","citation_count":24,"is_preprint":false},{"pmid":"26734995","id":"PMC_26734995","title":"HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26734995","citation_count":24,"is_preprint":false},{"pmid":"30575900","id":"PMC_30575900","title":"FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30575900","citation_count":23,"is_preprint":false},{"pmid":"30892941","id":"PMC_30892941","title":"Fra-1 plays a critical role in angiotensin II-induced vascular senescence.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30892941","citation_count":23,"is_preprint":false},{"pmid":"34907034","id":"PMC_34907034","title":"Transcription Factor FOSL1 Enhances Drug Resistance of Breast Cancer through DUSP7-Mediated Dephosphorylation of PEA15.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/34907034","citation_count":23,"is_preprint":false},{"pmid":"19558315","id":"PMC_19558315","title":"Fra-1/AP-1 impairs inflammatory responses and chondrogenesis in fracture healing.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19558315","citation_count":22,"is_preprint":false},{"pmid":"37160555","id":"PMC_37160555","title":"Exosome-transmitted FOSL1 from cancer-associated fibroblasts drives colorectal cancer stemness and chemo-resistance through transcriptionally activating ITGB4.","date":"2023","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37160555","citation_count":22,"is_preprint":false},{"pmid":"34188056","id":"PMC_34188056","title":"Fosl1 is vital to heart regeneration upon apex resection in adult Xenopus tropicalis.","date":"2021","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34188056","citation_count":22,"is_preprint":false},{"pmid":"22514284","id":"PMC_22514284","title":"Estrogen-induced expression of Fos-related antigen 1 (FRA-1) regulates uterine stromal differentiation and remodeling.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22514284","citation_count":22,"is_preprint":false},{"pmid":"39748430","id":"PMC_39748430","title":"FOSL1 transcriptionally dictates the Warburg effect and enhances chemoresistance in triple-negative breast cancer.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39748430","citation_count":21,"is_preprint":false},{"pmid":"33652085","id":"PMC_33652085","title":"Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33652085","citation_count":21,"is_preprint":false},{"pmid":"34712224","id":"PMC_34712224","title":"The Transcription Factor FRA-1/AP-1 Controls Lipocalin-2 Expression and Inflammation in Sepsis Model.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34712224","citation_count":21,"is_preprint":false},{"pmid":"36831172","id":"PMC_36831172","title":"Influence of FOSL1 Inhibition on Vascular Calcification and ROS Generation through Ferroptosis via P53-SLC7A11 Axis.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36831172","citation_count":21,"is_preprint":false},{"pmid":"22461694","id":"PMC_22461694","title":"Rhinovirus-induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22461694","citation_count":21,"is_preprint":false},{"pmid":"38367916","id":"PMC_38367916","title":"FOSL1 regulates hyperproliferation and NLRP3-mediated inflammation of psoriatic keratinocytes through the NF-kB signaling via transcriptionally activating TRAF3.","date":"2024","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38367916","citation_count":20,"is_preprint":false},{"pmid":"18096084","id":"PMC_18096084","title":"Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18096084","citation_count":20,"is_preprint":false},{"pmid":"34755654","id":"PMC_34755654","title":"The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression.","date":"2021","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34755654","citation_count":20,"is_preprint":false},{"pmid":"29914371","id":"PMC_29914371","title":"The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis.","date":"2018","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29914371","citation_count":20,"is_preprint":false},{"pmid":"21816965","id":"PMC_21816965","title":"Genetic disruption of Fra-1 decreases susceptibility to endotoxin-induced acute lung injury and mortality in mice.","date":"2012","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21816965","citation_count":20,"is_preprint":false},{"pmid":"31300541","id":"PMC_31300541","title":"AP-1 Signaling by Fra-1 Directly Regulates HMGA1 Oncogene Transcription in Triple-Negative Breast Cancers.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31300541","citation_count":19,"is_preprint":false},{"pmid":"34681621","id":"PMC_34681621","title":"FosL1 Is a Novel Target of Levetiracetam for Suppressing the Microglial Inflammatory Reaction.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34681621","citation_count":19,"is_preprint":false},{"pmid":"27442992","id":"PMC_27442992","title":"FOSL1 immunohistochemistry clarifies the distinction between desmoplastic fibroblastoma and fibroma of tendon sheath.","date":"2016","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27442992","citation_count":19,"is_preprint":false},{"pmid":"23758685","id":"PMC_23758685","title":"Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis.","date":"2013","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/23758685","citation_count":18,"is_preprint":false},{"pmid":"32271412","id":"PMC_32271412","title":"HOXA10 promotes the development of bladder cancer through regulating FOSL1.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32271412","citation_count":18,"is_preprint":false},{"pmid":"37642779","id":"PMC_37642779","title":"TRPM7 transactivates the FOSL1 gene through STAT3 and enhances glioma stemness.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37642779","citation_count":17,"is_preprint":false},{"pmid":"35658206","id":"PMC_35658206","title":"FRA-1: A key factor regulating signal transduction of tumor cells and a potential target molecule for tumor therapy.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/35658206","citation_count":17,"is_preprint":false},{"pmid":"19251936","id":"PMC_19251936","title":"Fra-1 negatively regulates lipopolysaccharide-mediated inflammatory responses.","date":"2009","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19251936","citation_count":17,"is_preprint":false},{"pmid":"30471098","id":"PMC_30471098","title":"Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30471098","citation_count":17,"is_preprint":false},{"pmid":"36672209","id":"PMC_36672209","title":"ABCA1-Mediated EMT Promotes Papillary Thyroid Cancer Malignancy through the ERK/Fra-1/ZEB1 Pathway.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36672209","citation_count":16,"is_preprint":false},{"pmid":"36634215","id":"PMC_36634215","title":"Fra-1 induces apoptosis and neuroinflammation by targeting S100A8 to modulate TLR4 pathways in spinal cord ischemia/reperfusion injury.","date":"2022","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36634215","citation_count":16,"is_preprint":false},{"pmid":"27388253","id":"PMC_27388253","title":"Copy number and expression analysis of FOSL1, GSTP1, NTSR1, FADD and CCND1 genes in primary breast tumors with axillary lymph node metastasis.","date":"2016","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27388253","citation_count":16,"is_preprint":false},{"pmid":"22235402","id":"PMC_22235402","title":"Effects of expression of transcriptional factor AP-1 FOSL1 gene on psoriatic process.","date":"2011","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22235402","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52245,"output_tokens":10318,"usd":0.155752,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21015,"output_tokens":4162,"usd":0.104563,"stage2_stop_reason":"end_turn"},"total_usd":0.260315,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"FRA-1 (fra-1) was identified as a serum-inducible immediate-early gene encoding a protein with extensive amino acid homology to c-Fos, including the region showing similarity to the yeast GCN4 regulatory protein and the Jun oncogene product. Unlike c-fos, fra-1 induction by serum was delayed, but it was induced rapidly in the presence of protein synthesis inhibitors, establishing it as an immediate-early gene.\",\n      \"method\": \"cDNA library screening with anti-Fos antibodies, nucleotide sequencing, Northern blot analysis of serum-stimulated rat fibroblasts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original molecular characterization with cloning, sequencing, and direct functional comparison; foundational paper replicated by entire field\",\n      \"pmids\": [\"3133553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron, which contain a consensus AP-1 site and two AP-1-like elements. Fra-1 protein fused to the Gal4 DNA-binding domain lacks transactivation function, yet overexpression of Fra-1 in rat fibroblasts confers anchorage-independent growth in vitro and tumor development in athymic mice, demonstrating oncogenic potential independent of classical transactivation.\",\n      \"method\": \"In vitro mutagenesis, stable transfection reporter assays, FosER induction system, soft-agar colony formation, nude mouse tumor assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, reporter assay, in vivo tumorigenesis), replicated concept\",\n      \"pmids\": [\"7791782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Exogenous expression of Fra-1 in epithelioid CSML0 carcinoma cells induces morphological fibroblastoid conversion, increases motility and in vitro invasiveness, and transcriptionally activates genes associated with late-stage tumor progression, establishing a direct causal role for Fra-1 in epithelial-to-mesenchymal-like transition.\",\n      \"method\": \"Retroviral transduction of Fra-1 into CSML0 cells, invasion assay, morphological analysis, AP-1 EMSA, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function with defined phenotypic readout, replicated by multiple subsequent studies\",\n      \"pmids\": [\"9819396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Fra-1 (but not c-Fos) expressed by retroviral transduction in osteoclast-macrophage precursor cell lines causes a 10–100-fold increase in the number of precursors developing calcitonin receptors and increased bone resorption, suggesting Fra-1 is a limiting factor for full osteoclast differentiation distinct from c-Fos.\",\n      \"method\": \"Retroviral gene transfer into osteoclast precursor cell lines, calcitonin receptor assay, bone resorption assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct gain-of-function in relevant cell type, single lab, two readouts\",\n      \"pmids\": [\"10199556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation: RANKL induces Fosl1 transcription in a c-Fos-dependent manner. All four Fos proteins (including Fra-1, which lacks transactivation domains) rescue the osteoclast differentiation block in c-fos-null mice when introduced by retroviral gene transfer; a Fra-1 transgene rescues osteopetrosis in c-fos-mutant mice in vivo.\",\n      \"method\": \"Retroviral gene transfer, transgenic mouse rescue, in vitro osteoclast differentiation assay, structure-function analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro and in vivo genetic rescue experiments with structure-function analysis, high-impact replicated findings\",\n      \"pmids\": [\"10655067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Fra-1 activates AP-1-dependent transcription in an ERK-dependent manner: a putative ERK phosphorylation site on Fra-1 must be intact for its transactivation activity. Fra-1 was identified as the distinguishing AP-1 component in mitogen-activated (transformation-sensitive) JB6 cells. Introduction of a Fra-1 expression construct into an AP-1-nonresponsive variant that underexpresses Fra-1 restored AP-1 response.\",\n      \"method\": \"Site-directed mutagenesis of Fra-1 transactivation domain, gel shift/EMSA analysis, AP-1 reporter assays, ERK-deficient cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of ERK phosphorylation site combined with rescue experiment in isogenic cell lines\",\n      \"pmids\": [\"11756554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal light-induced apoptosis. In knock-in mice expressing Fra-1 in place of c-Fos (Fos(Fosl1/Fosl1)), morphological features of apoptosis and AP-1 activity were indistinguishable from wild-type, demonstrating that Fra-1 can mediate both pro- and anti-apoptotic signaling without classic transactivation domains.\",\n      \"method\": \"Knock-in mouse model, light-damage apoptosis assay, AP-1 EMSA/supershift, histology\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic knock-in model with multiple orthogonal readouts\",\n      \"pmids\": [\"11953459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MEK5-ERK5 pathway activation causes phosphorylation and stabilization of Fra-1, and the C-terminal half of ERK5 is required for maximal activation of Fra-1 transactivation activity. The MEK5-ERK5 pathway-dependent phosphorylation sites on Fra-1 are distinct from those of the ERK1/2 pathway.\",\n      \"method\": \"Constitutively active MEK5 expression, kinase inhibitor experiments, transactivation reporter assays, phosphorylation analysis\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporters and phosphorylation analyses, single lab\",\n      \"pmids\": [\"12622723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ras oncogene-dependent accumulation of Fra-1 requires both transcriptional autoregulation (via an AP-1 site in the fra-1 first intron occupied by Fra-1-containing complexes) and MEK/ERK-dependent posttranslational stabilization that dramatically increases Fra-1 protein half-life. Fra-1 transactivating activity in ras-transformed cells requires heterodimerization with a partner protein.\",\n      \"method\": \"Retroviral transformation of thyroid cells, chromatin immunoprecipitation, MEK inhibitor treatment, protein half-life analysis, transcriptional reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (ChIP, protein stability, reporter assay, MEK inhibition) in single rigorous study\",\n      \"pmids\": [\"12773579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Fra-1 targets the AP-1 site adjacent to the 2G SNP in the MMP-1 promoter and is necessary for MMP-1 transcription in A2058 melanoma cells. Inhibition of Fra-1 expression preferentially downregulates transcription from the 2G SNP-containing MMP-1 promoter compared to the 1G SNP version.\",\n      \"method\": \"Fra-1 siRNA/antisense inhibition, MMP-1 promoter reporter assays with 1G vs 2G SNP constructs\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with promoter variant readout, single lab\",\n      \"pmids\": [\"14519134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Fra-1 and Stat3 synergistically activate the MMP-9 gene promoter. DNA affinity precipitation and co-immunoprecipitation identified Stat3/Fra-1 and Stat3/c-Jun complexes in vivo, with c-Jun recruited to the Stat3-Fra-1 complex. A juxtaposed Stat3/AP-1 element in the MMP-9 promoter functions as an enhancersome. Neither Fra-1 alone nor Stat3 alone was sufficient for MMP-9 promoter activation.\",\n      \"method\": \"Luciferase reporter assays, DNA affinity precipitation assay, co-immunoprecipitation, promoter mutagenesis\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and functional reporter assay, single lab\",\n      \"pmids\": [\"17572495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Ubiquitin-independent proteasomal degradation is a major pathway for Fra-1 turnover. Fra-1 shares a conserved destabilizing domain with c-Fos. Under particular conditions a fraction of cytoplasmic c-Fos is ubiquitylated leading to faster turnover, indicating multiple degradation pathways can target Fra-1 depending on activation state, protein partnership, and subcellular localization.\",\n      \"method\": \"Protein stability assays, proteasome inhibitor treatment, mutagenesis of destabilizing domains, subcellular fractionation\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic review with original data synthesis; degradation pathway established by multiple earlier experiments summarized\",\n      \"pmids\": [\"17825471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fra-1 binds to the MGP promoter in response to inorganic phosphate in osteoblasts, as demonstrated by in vitro DNA binding and chromatin immunoprecipitation assays. Pi-dependent induction of MGP is mediated through the ERK1/2-Fra-1 pathway: MEK1/2 inhibition abolishes Pi-stimulated Fra-1 and MGP expression, and primary osteoblasts from Fra-1-deficient mice fail to show Pi-dependent MGP upregulation.\",\n      \"method\": \"Chromatin immunoprecipitation, in vitro DNA binding assay, MEK inhibitor (U0126), Fra-1-deficient mouse primary osteoblasts, siRNA knockdown\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus genetic knockout confirmation plus pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"19419315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Fra-1 binds to the interleukin-6 (IL-6) promoter in macrophages to increase IL-6 production. IL-6 then acts in an autocrine fashion to skew macrophage differentiation into M2d macrophages. Fra-1 overexpression is induced in macrophages by tumor cell co-culture.\",\n      \"method\": \"ChIP assay, co-culture experiments, IL-6 promoter binding analysis, macrophage differentiation assay\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and functional co-culture assay, single lab\",\n      \"pmids\": [\"20386569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Heterodimerization of Fra-1 with c-Jun stabilizes c-Jun in RAS-transformed cells. ERK pathway activity and Fra-1/c-Jun heterodimerization cooperate to prevent c-Jun proteasomal breakdown; phosphorylation of the Fra-1 C-terminal domain (which controls Fra-1 stability in response to ERK signaling) is required for this stabilizing effect on c-Jun.\",\n      \"method\": \"Co-immunoprecipitation, protein half-life analysis, ERK inhibitor treatment, constitutively transformed thyroid cell lines, dimerization-deficient Fra-1 mutants\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted mechanism with mutagenesis, reciprocal Co-IP, and pharmacological dissection in same study\",\n      \"pmids\": [\"20543861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FOSL1 is a downstream effector of the PI3K/AKT signaling pathway in trophoblast cells. Nuclear FOSL1 increases during trophoblast differentiation in a PI3K/AKT-dependent manner. FOSL1 occupies the Mmp9 promoter in trophoblast cells (ChIP) and regulates Mmp9 expression; knockdown of FOSL1 abrogates trophoblast invasion in vitro and in vivo (lentiviral shRNA).\",\n      \"method\": \"PI3K/AKT inhibitors, AKT isoform-specific siRNA, ChIP, lentiviral shRNA in vivo, trophoblast invasion assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus in vivo lentiviral KD with invasion readout, multiple orthogonal methods\",\n      \"pmids\": [\"21947281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Fra-1 directly suppresses the adipogenic transcription factor C/EBPα (Cebpa) by binding to the Cebpa promoter, thereby autonomously blocking adipocyte differentiation. Fra-1 transgenic mice develop severe lipodystrophy with reduced adipogenic markers; Fra-1 overexpression in adipogenic cell lines blocks their differentiation.\",\n      \"method\": \"Fra-1 transgenic mice, primary transgenic osteoblast adipogenic differentiation assay, promoter binding/ChIP assay, adipogenic cell line overexpression\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus transgenic mouse plus cell-autonomous differentiation assay\",\n      \"pmids\": [\"21486951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fra-1 preferentially associates with c-Jun and binds to the promoter regions of the cyclin-dependent kinase inhibitor genes p21 (Cdkn1a) and p16 (Cdkn2a), leading to their transcriptional upregulation and induction of vascular senescence phenotypes in response to angiotensin II.\",\n      \"method\": \"Co-immunoprecipitation (Fra-1/c-Jun interaction), chromatin immunoprecipitation (p21 and p16 promoters), Fra-1 siRNA knockdown, senescence-associated β-galactosidase assay, in vivo Ang II infusion model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus in vivo model, single lab\",\n      \"pmids\": [\"30892941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fra-1 directly regulates MMP-9 expression in rhinovirus-infected bronchial epithelial cells. AP-1 sites in the MMP-9 promoter are required for HRV-induced MMP-9 promoter drive; EMSA/supershift identified Fra-1 in AP-1 complexes bound to the MMP-9 promoter; siRNA knockdown of Fra-1 abolished MMP-9 expression. MEK1/2 inhibition reduced Fra-1 expression and MMP-9. Formoterol and dexamethasone suppress Fra-1 and MMP-9 via reduced ERK phosphorylation.\",\n      \"method\": \"Site-directed mutagenesis of AP-1 sites, EMSA with supershift, siRNA knockdown, MEK inhibitors, pharmacological treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA/supershift plus siRNA with multiple confirmatory approaches, single lab\",\n      \"pmids\": [\"22461694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Estrogen receptor α (ESR1) directly recruits to an estrogen response element in the Fra-1 promoter (demonstrated by ChIP), regulating Fra-1 expression in uterine stromal cells. Fra-1 in turn controls MMP9 and MMP13 expression critical for stromal extracellular matrix remodeling during decidualization. Fra-1 knockdown during in vitro decidualization blocks stromal differentiation and cell migration.\",\n      \"method\": \"ChIP (ESR1 binding to Fra-1 promoter), siRNA-mediated ESR1 silencing, Fra-1 knockdown, in vitro decidualization assay, migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus siRNA knockdown with differentiation/migration readout, single lab\",\n      \"pmids\": [\"22514284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fra-1 induces EMT in mammary epithelial cells by directly binding to the tgfb1 and zeb2 promoters and to an evolutionarily conserved region in the first intron of zeb1, increasing expression of TGFβ1, Zeb1, Zeb2, and Slug. Silencing of zeb1 or zeb2 (but not TGFβ inhibition alone) fully restored epithelial phenotype and decreased invasion, placing Zeb1/Zeb2 downstream of Fra-1 in EMT.\",\n      \"method\": \"ChIP (Fra-1 binding to tgfb1, zeb1, zeb2 loci), luciferase reporter assays, siRNA knockdown, ectopic Fra-1 expression in EpH4 cells, in vivo transplantation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus reporter assays plus genetic epistasis (siRNA rescue) plus in vivo tumor model, multiple methods\",\n      \"pmids\": [\"25301070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fra-1 controls transcription of the uPA/Plau gene in metastatic breast cancer cells via binding to two AP-1 enhancers (ABR-1.9 and ABR-4.1, located ~1.9 and ~4.1 kb upstream of the TSS), promoting RNA Pol II recruitment and productive transcription of Plau-001 mRNA; Fra-1 also tempers expression of a minor Plau-004 transcript from ABR-1.9.\",\n      \"method\": \"ChIP, pharmacological inhibition, RNAi, RNA Pol II ChIP, chromosome conformation capture (3C)\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP, 3C, and RNAi combined with transcriptional run-on; multiple orthogonal methods\",\n      \"pmids\": [\"25200076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOSL1 is a negative regulator of type I interferon (IFN-I) signaling. Upon stimulation with poly(I:C), malaria-infected RBCs, or VSV, FOSL1 translocates from the nucleus to the cytoplasm where it inhibits interactions between TRAF3, TRIF, and TBK1 by impairing K63-linked polyubiquitination of TRAF3 and TRIF. FOSL1 knockout chimeric mice show lower parasitemia/viral titers and decreased mortality.\",\n      \"method\": \"Co-immunoprecipitation (TRAF3/TRIF/TBK1 interactions), ubiquitination assays, FOSL1 knockout chimeric mice, cellular fractionation/localization, poly(I:C) and viral stimulation\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical mechanism (ubiquitination + protein interactions) validated in vivo with KO mice, multiple orthogonal methods\",\n      \"pmids\": [\"28049150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOSL1 is the main immediate-early AP-1 member induced by melanoma oncogenes and acts oncogenically by transcriptionally activating HMGA1. FOSL1 transforms melanocytes, downregulates MITF in a HMGA1-dependent manner, upregulates AXL, and re-enforces MYC, E2F3, and AP-1, enabling subcutaneous tumor growth in vivo. HMGA1 mediates FOSL1-driven migration, proliferation, and anoikis-independent growth.\",\n      \"method\": \"siRNA knockdown, ectopic expression, in vivo melanocyte transformation assay, gene expression profiling, promoter analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with in vivo transformation and mechanistic epistasis (HMGA1 dependence), single lab\",\n      \"pmids\": [\"28481878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MLK3 kinase drives invasion in TNBC cells through FRA-1: MLK3 expression robustly upregulates FRA-1 in breast cancer cells, accompanied by elevation of MMP-1 and MMP-9; FRA-1 silencing abrogates MLK3-induced invasion. MLK3 depletion (siRNA or CRISPR) significantly reduces FRA-1 and MMP-1/MMP-9 levels and decreases transendothelial migration.\",\n      \"method\": \"Inducible MLK3 expression, FRA-1 siRNA, CRISPR/Cas9n MLK3 deletion, invasion assay, transendothelial migration assay, MMP expression\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established with both siRNA and CRISPR, single lab\",\n      \"pmids\": [\"28604765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Integrin αVβ3/uPAR signaling leads to FAK-SRC-ERK2-mediated phosphorylation and stabilization of FRA-1, enhancing breast cancer invasion on vitronectin. Transient knockdown of uPAR reduces FRA-1 phosphorylation and stabilization; both uPAR and FRA-1 are required for vitronectin-induced invasion.\",\n      \"method\": \"Pharmacological inhibitors (FAK, SRC, ERK), uPAR siRNA knockdown, FRA-1 phosphorylation immunoblot, invasion assay on vitronectin\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection plus siRNA epistasis with mechanistic phosphorylation readout, single lab\",\n      \"pmids\": [\"29382358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fra-1 directly binds to the arginase-1 (Arg1) promoter in macrophages (demonstrated by ChIP-seq and standard ChIP) and transcriptionally represses Arg1 expression. Macrophage-specific Fra-1-deficient mice show enhanced Arg1 expression/activity and reduced arthritis severity; the phenotype is reversed by arginase inhibition, placing Fra-1 upstream of Arg1 in macrophage inflammatory regulation.\",\n      \"method\": \"ChIP-seq, standard ChIP, luciferase reporter assay, macrophage-specific conditional Fra-1 KO mice, arginase inhibitor treatment, arthritis model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP-seq plus ChIP plus reporter assay plus conditional KO mouse with pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"30990796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fra-1 directly regulates HMGA1 gene transcription in TNBC cells by binding to enhancer elements in the last two introns of HMGA1. Fra-1 binding is required for RNA Polymerase II recruitment at the HMGA1 promoter through pre-existing chromatin loops linking intragenic enhancers to the promoter; Fra-1 is not required for chromatin loop formation but exploits pre-existing interactions.\",\n      \"method\": \"ChIP, RNAi, transcriptional run-on assay, chromosome conformation capture (3C), mRNA analysis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus 3C plus transcriptional run-on with RNAi validation, multiple orthogonal methods\",\n      \"pmids\": [\"31300541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PARP1 interacts with and downregulates Fra-1, reducing AP-1 transcriptional activity. Olaparib treatment or PARP1 silencing increases Fra-1 levels and AP-1 transcriptional activity. A large fraction of PARP1-regulated genes was dependent on Fra-1, as established by large-scale chromatin-bound Fra-1 proteomics screen identifying PARP1 among 118 Fra-1-interacting proteins.\",\n      \"method\": \"Co-immunoprecipitation (endogenous Fra-1-PARP1), AP-1 reporter assays, PARP1 inhibitor (olaparib), PARP1 siRNA, proteomic screen of chromatin-bound Fra-1\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional reporter assay plus pharmacological and genetic perturbation, single lab\",\n      \"pmids\": [\"33652085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOSL1 promotes HNSCC metastasis predominantly through selective association with Mediator complex components to establish super-enhancers (SEs) at cancer stemness and pro-metastatic genes including SNAI2 and FOSL1 itself. Depletion of FOSL1 disrupts SEs and inhibits expression of these oncogenes.\",\n      \"method\": \"ChIP-seq for SE analysis, Mediator co-association assay, FOSL1 knockdown, patient-derived xenograft model, spontaneous mouse model\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus in vivo PDX model, single lab\",\n      \"pmids\": [\"33794365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOSL1 promotes proneural-to-mesenchymal transition (PMT) in glioblastoma stem cells via UBC9-dependent CYLD SUMOylation. FOSL1 facilitates UBC9-mediated SUMOylation of CYLD, inducing K63-linked polyubiquitination of NF-κB intermediaries and NF-κB activation, which drives PMT.\",\n      \"method\": \"siRNA knockdown, ectopic expression, SUMOylation assay, ubiquitination assay, NF-κB reporter, in vivo tumor-initiating assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical mechanism (SUMOylation/ubiquitination) with functional rescue, single lab\",\n      \"pmids\": [\"35351656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fosl1 interacts with JunB and promotes expression of Cyclin-T1 (Ccnt1) during heart regeneration, driving cardiomyocyte proliferation. Demonstrated by Co-immunoprecipitation (Fosl1/JunB interaction), luciferase reporter assays, and ChIP analysis. Cardiomyocyte-specific dominant-negative Fosl1 impairs cardiomyocyte proliferation in X. tropicalis; Fosl1 knockdown suppresses neonatal mouse heart regeneration while overexpression improves cardiac function after myocardial infarction.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, ChIP, cardiomyocyte-specific dominant-negative transgene, siRNA knockdown, in vivo heart injury models\",\n      \"journal\": \"NPJ Regenerative medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus multiple in vivo models, single lab\",\n      \"pmids\": [\"34188056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SMAD4 represses FOSL1 expression, and FOSL1 is sufficient to drive metastatic colonization to the lung as identified in an in vivo genetic screen using isogenic SMAD4-deleted pancreatic cancer cell lines.\",\n      \"method\": \"Isogenic SMAD4 cell lines, in vivo metastasis screen, FOSL1 overexpression\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo functional screen with isogenic lines establishing pathway position, single lab\",\n      \"pmids\": [\"34320363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOSL1 binds to the Klotho promoter (demonstrated by ChIP enrichment) and preserves Klotho expression during acute kidney injury. Selective Fosl1 deficiency in proximal tubular cells (Fosl1Δtub) worsens AKI, reduces Klotho, and increases NF-κB/AP-1 activity; recombinant Klotho administration rescues Fosl1Δtub mice from cisplatin-AKI, placing Klotho downstream of Fosl1.\",\n      \"method\": \"ChIP (Fosl1 binding to Klotho promoter), conditional tubular-specific Fosl1 KO mice, cisplatin/folate AKI models, recombinant Klotho rescue\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus conditional KO mouse plus pharmacological rescue establishing pathway position\",\n      \"pmids\": [\"36565807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOSL1 and FOSL2 co-repress Th17 fate-specification in human T cells, contrasting with BATF which promotes the Th17 lineage. Genome-wide binding analysis revealed FOSL1, FOSL2, and BATF share occupancy over regulatory regions of Th17 commitment genes and share protein-interacting partners, suggesting a competitive mechanism.\",\n      \"method\": \"Genome-wide ChIP-seq binding analysis, siRNA-mediated knockdown, Th17 differentiation assay, protein interaction mapping\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus functional differentiation assay, single lab\",\n      \"pmids\": [\"35511484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOSL1 positively regulates DUSP7 transcription in doxorubicin-resistant breast cancer cells, and DUSP7 promotes dephosphorylation of PEA15, enhancing drug resistance. This FOSL1/DUSP7/PEA15 pathway was established by ChIP (FOSL1 binding to DUSP7 promoter) and functional rescue experiments.\",\n      \"method\": \"ChIP (FOSL1 binding to DUSP7 promoter), siRNA knockdown, overexpression, in vitro and in vivo drug resistance assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional rescue, single lab\",\n      \"pmids\": [\"34907034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOSL1 deacetylation at Lys-116 within its DNA binding domain increases its transcriptional activity. TRPM7 induces FOSL1 transcriptional activation via STAT3, which binds to GAS elements at -328 to -336 and -378 to -386 in the FOSL1 promoter (confirmed by ChIP-qPCR). FOSL1 promotes glioma stem cell marker expression and maintains stem cell activity.\",\n      \"method\": \"Luciferase reporter with GAS element mutants, ChIP-qPCR, constitutively active/dominant-negative STAT3, FOSL1 acetylation/deacetylation assay\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR plus reporter mutagenesis plus PTM identification, single lab\",\n      \"pmids\": [\"37642779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CYTOR (a nuclear lncRNA) facilitates formation of FOSL1 phase-separated condensates and FOSL1-dependent super-enhancers to drive cancer stemness and pro-metastatic gene expression in HNSCC tumor budding cells. In turn, FOSL1 activation promotes CYTOR transcription, forming a feedback loop. Depletion of CYTOR disrupts FOSL1-dependent SEs.\",\n      \"method\": \"Phase separation assay, ChIP-seq for SE analysis, CYTOR/FOSL1 knockdown, in vivo tumor growth and lymph node metastasis model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phase separation assay plus ChIP-seq plus in vivo model, single lab\",\n      \"pmids\": [\"38032139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CAF-derived exosomal FOSL1 is transferred to colorectal cancer cells and transcriptionally activates ITGB4 (integrin β4), promoting CRC cell proliferation, stemness, and oxaliplatin resistance. Transcriptional activation of ITGB4 by FOSL1 was confirmed by ChIP and dual-luciferase reporter assays.\",\n      \"method\": \"Exosome isolation, ChIP assay, dual-luciferase reporter assay, FOSL1 overexpression/knockdown, co-culture with CAF-conditioned medium, exosome inhibitor GW4869\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus exosome transfer experiment, single lab\",\n      \"pmids\": [\"37160555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOSL1 transcriptionally activates glycolytic genes SLC2A1, ENO1, and LDHA in TNBC cells, enhancing the Warburg effect. FOSL1 promotes tumor growth in a glycolysis-dependent manner (2-DG abolishes FOSL1 oncogenic effects). Established by ChIP and luciferase reporter assays.\",\n      \"method\": \"ChIP, luciferase reporter assay, glucose uptake/lactate/ECAR measurements, 2-DG inhibition, xenograft model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus metabolic rescue experiment, single lab\",\n      \"pmids\": [\"39748430\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOSL1/FRA-1 is a FOS-family bZIP transcription factor that heterodimerizes with JUN partners to form AP-1 complexes; it lacks classical transactivation domains but is oncogenically activated downstream of RAS-RAF-MEK-ERK signaling (and PI3K/AKT), which phosphorylates and stabilizes the protein via MEK/ERK-dependent posttranslational mechanisms. Fra-1 accumulation is maintained by transcriptional autoregulation through an AP-1 site in its first intron. It drives invasion, EMT, and metastasis by directly binding to and activating promoters/enhancers of target genes including ZEB1, ZEB2, TGFβ1, MMP-1, MMP-9, HMGA1, ITGB4, SLC2A1, ENO1, and LDHA, and represses genes such as Arg1 and C/EBPα; it also assembles super-enhancers via Mediator association. Beyond nuclear transcription, Fra-1 translocates to the cytoplasm upon innate immune stimulation where it blocks TRAF3/TRIF/TBK1 interactions to suppress type I interferon responses. Fra-1 additionally stabilizes its dimerization partner c-Jun through an ERK-dependent heterodimerization mechanism.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOSL1 (FRA-1) is a serum-inducible immediate-early FOS-family bZIP transcription factor that, despite lacking classical transactivation domains, functions as an AP-1 component to drive tumor invasion, epithelial-to-mesenchymal transition, and metastasis [#0, #2, #20]. Its accumulation in oncogenically transformed cells is established by a dual mechanism: transcriptional autoregulation through an AP-1 site in its own first intron, and RAS-MEK/ERK-dependent posttranslational stabilization that markedly extends protein half-life [#1, #8]; this stabilization depends on an intact ERK phosphorylation site, and analogous MEK5-ERK5 phosphorylation and integrin \\u03b1V\\u03b23/uPAR\\u2013FAK-SRC-ERK2 signaling converge to control FRA-1 activity and turnover [#5, #7, #25]. FRA-1 transactivation requires heterodimerization with JUN-family partners, and FRA-1/c-Jun heterodimerization reciprocally stabilizes c-Jun in an ERK-dependent manner [#8, #14]. As a sequence-specific factor it directly binds promoters and intragenic/enhancer elements to activate a pro-invasive and pro-metastatic program, including the EMT regulators ZEB1, ZEB2, and TGF\\u03b21, the matrix protease genes MMP-1, MMP-9, and PLAU/uPA, the oncogene HMGA1, integrin ITGB4, and the glycolytic genes SLC2A1, ENO1, and LDHA, while repressing differentiation genes such as C/EBP\\u03b1 and the macrophage gene Arg1 [#16, #20, #21, #26, #27, #39]. FRA-1 frequently exploits pre-existing chromatin loops to recruit RNA Polymerase II and assembles Mediator-associated super-enhancers at stemness and pro-metastatic loci [#27, #29]. Genetically, FRA-1 can substitute for c-Fos in vivo, rescuing osteopetrosis in c-fos-mutant mice, and acts as a limiting factor for osteoclast differentiation [#3, #4]. Beyond cancer it has tissue-protective and immunoregulatory roles: it preserves Klotho during acute kidney injury, drives cardiomyocyte proliferation during heart regeneration via JunB, and acts as a negative regulator of type I interferon signaling by translocating to the cytoplasm to block TRAF3/TRIF/TBK1 assembly [#22, #31, #33].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established FRA-1 as a distinct FOS-family immediate-early gene, answering whether the Fos-related antigen was an independent serum-responsive regulator rather than a c-Fos artifact.\",\n      \"evidence\": \"cDNA cloning, sequencing, and Northern analysis of serum-stimulated rat fibroblasts\",\n      \"pmids\": [\"3133553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define DNA-binding specificity or dimer partners\", \"No functional role assigned\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Showed FRA-1 is oncogenic and autoregulated despite lacking a classical transactivation domain, reframing how a transactivation-deficient factor could transform cells.\",\n      \"evidence\": \"Intron mutagenesis, Gal4-fusion transactivation assays, soft-agar and nude-mouse tumorigenesis\",\n      \"pmids\": [\"7791782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of transactivation-independent transformation not resolved\", \"Required dimer partner unidentified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated a direct causal role for FRA-1 in epithelial-to-mesenchymal-like conversion and invasion, linking it to late-stage tumor progression.\",\n      \"evidence\": \"Retroviral FRA-1 expression in CSML0 carcinoma cells with invasion, morphology, and EMSA readouts\",\n      \"pmids\": [\"9819396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes of the EMT program not yet identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic rescue experiments established FRA-1 as a functional in vivo substitute for c-Fos and a RANKL/c-Fos-driven effector in osteoclast differentiation.\",\n      \"evidence\": \"Retroviral rescue and transgenic rescue of c-fos-null osteopetrosis, in vitro osteoclast assays (also [#3])\",\n      \"pmids\": [\"10655067\", \"10199556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes downstream of FRA-1 in osteoclasts not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved how FRA-1 accumulates in transformed cells, establishing combined intronic autoregulation and MEK/ERK-dependent protein stabilization as the basis for RAS-driven accumulation.\",\n      \"evidence\": \"ChIP, MEK inhibition, protein half-life and reporter assays in ras-transformed cells; ERK-site mutagenesis (also [#5, #7])\",\n      \"pmids\": [\"12773579\", \"11756554\", \"12622723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the obligate heterodimer partner in transformed cells not pinned down here\", \"ERK5 versus ERK1/2 site contributions only partially separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a reciprocal regulatory mechanism by which FRA-1/c-Jun heterodimerization stabilizes c-Jun, coupling FRA-1 stability and dimerization to AP-1 output.\",\n      \"evidence\": \"Co-IP, protein half-life, ERK inhibition, and dimerization-deficient FRA-1 mutants in transformed thyroid cells\",\n      \"pmids\": [\"20543861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation machinery for c-Jun in this context not fully defined\", \"Ubiquitin-independent versus -dependent turnover of FRA-1 itself only partly characterized ([#11])\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified the direct transcriptional targets through which FRA-1 enforces EMT, placing ZEB1/ZEB2 epistatically downstream of FRA-1.\",\n      \"evidence\": \"ChIP at tgfb1/zeb1/zeb2 loci, reporter assays, siRNA epistasis, and in vivo transplantation (with PLAU enhancer mapping in [#21])\",\n      \"pmids\": [\"25301070\", \"25200076\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of FRA-1 among AP-1 dimers at these loci not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a non-transcriptional, cytoplasmic function for FOSL1 as a negative regulator of type I interferon signaling, expanding its role beyond nuclear AP-1.\",\n      \"evidence\": \"Co-IP of TRAF3/TRIF/TBK1, ubiquitination assays, fractionation, and FOSL1-KO chimeric mice challenged with poly(I:C)/virus/malaria\",\n      \"pmids\": [\"28049150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering nuclear-to-cytoplasmic translocation not defined\", \"Structural basis of TRAF3/TRIF interference unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed FRA-1 acts on chromatin via pre-existing loops and ChIP-seq-scale target programs, including transcriptional repression of Arg1 in macrophages.\",\n      \"evidence\": \"ChIP-seq, 3C, transcriptional run-on, conditional macrophage Fra-1 KO with arginase rescue (also HMGA1 enhancer looping in [#27])\",\n      \"pmids\": [\"30990796\", \"31300541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of activator versus repressor behavior at different loci unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected FOSL1 to super-enhancer assembly and tissue-protective/regenerative roles, broadening its mechanism to Mediator co-association and condensate formation.\",\n      \"evidence\": \"ChIP-seq super-enhancer mapping with Mediator co-association in HNSCC, JunB Co-IP/ChIP in heart regeneration, and SMAD4-repression metastasis screen (also [#37, #33])\",\n      \"pmids\": [\"33794365\", \"34188056\", \"34320363\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mediator-selectivity mechanism not biochemically dissected\", \"Single-lab models for each tissue context\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended the FOSL1 target program to metabolic reprogramming and post-translational/upstream control, including STAT3-driven induction and DNA-binding-domain acetylation.\",\n      \"evidence\": \"ChIP and reporter assays for glycolytic genes (SLC2A1/ENO1/LDHA) with 2-DG rescue, plus STAT3/TRPM7 and Lys-116 deacetylation studies (also [#33, #38])\",\n      \"pmids\": [\"39748430\", \"37642779\", \"36565807\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes controlling Lys-116 acetylation not identified\", \"Many target programs validated in single cell systems\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FOSL1 selects among AP-1 dimer partners and target loci to switch between activator, repressor, super-enhancer-organizing, and cytoplasmic IFN-suppressing roles remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking phosphorylation/acetylation state to partner choice and locus selection\", \"Signal governing nuclear-cytoplasmic partitioning undefined\", \"Structural basis of transactivation-domain-independent activity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 16, 20, 21, 26, 27, 39]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 12, 20, 26, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 15, 20, 27]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 20, 21, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 8, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 20, 29, 39]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [22, 26, 34]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 16, 20, 31]}\n    ],\n    \"complexes\": [\"AP-1\", \"Mediator-associated super-enhancer\"],\n    \"partners\": [\"JUN\", \"JUNB\", \"STAT3\", \"PARP1\", \"TRAF3\", \"MED (Mediator)\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}